Clinical Trial Update: Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating NovoSeven (recombinant Factor VIIa) for restoring coagulation activation in Hemophilia A has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Medical University of Vienna | Conditions: Hemophilia A | Phase 3 | Status: COMPLETED